Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

NCT04092673 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: eFT226
DRUG: Sotorasib
DRUG: Fulvestrant
DRUG: Abemaciclib
DRUG: Trastuzumab

Sponsor

Effector Therapeutics